StreetInsider.com News Articles

Leerink Partners Reiterates Market Perform Rating on Century Therapeutics (IPSC)

Fri, 13 Mar 2026 08:24:56 -0400

Leerink Partners analyst Daina Graybosch reiterated a Market Perform rating and $2.00 price target on Century Therapeutics (NASDAQ: IPSC).

The analyst comments "We are increasingly appreciative of the clinically transformative potential of Century’s lead iPSC-derived beta islet cell therapy for Type 1 Diabetes (T1D), CNTY-813, but reiterate our MP rating on IPSC as we still see uncertainty with the program’s remaining technical hurdles ahead of first-in-human testing and data in 2H27. ● What Happened: Century Therapeutics reported 4Q25/FY25 earnings and provided a corporate and pipeline update in a press release (PR, slide deck). We also hosted Century management for a fireside

Form 144 Century Therapeutics, Filed by: Russotti Gregory

Thu, 12 Mar 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260312/26153561.html

Form 144 Century Therapeutics, Filed by: Russotti Gregory

Thu, 12 Mar 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260312/26153561.html

Form S-8 Century Therapeutics,

Thu, 12 Mar 2026 08:27:00 -0400

si-local-file:///var/storage/secattach/20260312/26149807.html

Form S-8 Century Therapeutics,

Thu, 12 Mar 2026 08:27:00 -0400

si-local-file:///var/storage/secattach/20260312/26149807.html

Form 8-K Century Therapeutics, For: Mar 12

Thu, 12 Mar 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260312/26149677.html

Form 8-K Century Therapeutics, For: Mar 12

Thu, 12 Mar 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260312/26149677.html

Form 10-K Century Therapeutics, For: Dec 31

Thu, 12 Mar 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260312/26149667.html

Form 10-K Century Therapeutics, For: Dec 31

Thu, 12 Mar 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260312/26149667.html

Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Thu, 12 Mar 2026 08:00:00 -0400

CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H 2027
CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, on track to enter the clinic in 2026
Strengthened balance sheet and cash runway extended into 1Q 2029 from oversubscribed $135 million private placement in January 2026

PHILADELPHIA, March 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell

Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Thu, 12 Mar 2026 08:00:00 -0400

CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H 2027
CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, on track to enter the clinic in 2026
Strengthened balance sheet and cash runway extended into 1Q 2029 from oversubscribed $135 million private placement in January 2026

PHILADELPHIA, March 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell

Form 4 Century Therapeutics, For: Mar 09 Filed by: Carr Douglas

Wed, 11 Mar 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260311/26146159.html

Form 4 Century Therapeutics, For: Mar 09 Filed by: Carr Douglas

Wed, 11 Mar 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260311/26146159.html

Form 4 Century Therapeutics, For: Mar 09 Filed by: Russotti Gregory

Wed, 11 Mar 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260311/26146166.html

Form 4 Century Therapeutics, For: Mar 09 Filed by: Russotti Gregory

Wed, 11 Mar 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260311/26146166.html

Form 4 Century Therapeutics, For: Mar 06 Filed by: Pfeiffenberger Brent

Tue, 10 Mar 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20260310/26141255.html

Form 4 Century Therapeutics, For: Mar 06 Filed by: Pfeiffenberger Brent

Tue, 10 Mar 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20260310/26141255.html

Form 144 Century Therapeutics, Filed by: Russotti Gregory

Mon, 09 Mar 2026 15:15:00 -0400

si-local-file:///var/storage/secattach/20260309/26131595.html

Form 144 Century Therapeutics, Filed by: Russotti Gregory

Mon, 09 Mar 2026 15:15:00 -0400

si-local-file:///var/storage/secattach/20260309/26131595.html

Century Therapeutics to Participate in Upcoming Investor Conferences in March

Wed, 25 Feb 2026 08:00:00 -0400

PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March:

TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA.
Leerink Partners Global Healthcare Conference: Fireside chat at 4:20 p.m. ET on Tuesday, March 10, 2026, in Miami, FL.

A live

Century Therapeutics to Participate in Upcoming Investor Conferences in March

Wed, 25 Feb 2026 08:00:00 -0400

TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA.
Leerink Partners Global Healthcare Conference: Fireside chat at 4:20 p.m. ET on Tuesday, March 10, 2026, in Miami, FL.

A live

TD Cowen Starts Century Therapeutics (IPSC) at Buy

Wed, 25 Feb 2026 05:29:45 -0400

TD Cowen analyst Phil Nadeau initiates coverage on Century Therapeutics (NASDAQ: IPSC) with a Buy rating.

The analyst comments "Century develops potentially curative allogeneic stem cell therapies. Century's lead is CNTY-813, an allogeneic insulin-expressing beta islet cell therapy for type 1 diabetes that has produced intriguing preclinical data. It is expected to enter the clinic in 2026 and generate initial data in 2027. We expect IPSC to create long-term shareholder value as its pipeline advances through development."

For an analyst ratings summary and ratings history on Century Therapeutics click here. For more ratings news on Century Therapeutics click here.

Shares of

TD Cowen Starts Century Therapeutics (IPSC) at Buy

Wed, 25 Feb 2026 05:29:45 -0400

TD Cowen analyst Phil Nadeau initiates coverage on Century Therapeutics (NASDAQ: IPSC) with a Buy rating.

For an analyst ratings summary and ratings history on Century Therapeutics click here. For more ratings news on Century Therapeutics click here.

Shares of

Form 4 Century Therapeutics, For: Feb 13 Filed by: Pfeiffenberger Brent

Wed, 18 Feb 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260218/26023515.html

Form 4 Century Therapeutics, For: Feb 13 Filed by: Pfeiffenberger Brent

Wed, 18 Feb 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260218/26023515.html